Fluconazole Use Doesn't Up Risk of Stillbirth, Neonatal Death
THURSDAY, June 14, 2018 -- Fluconazole use in pregnancy seems not to be associated with significantly increased risks of stillbirth or neonatal death, according to a research letter published in the June 12 issue of the Journal of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2018 Category: Pharmaceuticals Source Type: news
Oral Fluconazole for Thrush in Pregnancy Doesn't Up Stillbirth Oral Fluconazole for Thrush in Pregnancy Doesn't Up Stillbirth
Oral fluconazole at any dose was not associated with an increased risk of stillbirth or neonatal death but more research is needed to guide clinical decision-making.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2018 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news
Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice
The activities ofR-135853, a novel sordarin derivative that possesses a 1,4-oxazepane ring moiety, were evaluated in vitro and in vivo.R-135853 exhibited potent in vitro activities against Candida albicans (fluconazole-susceptible strains), Candida glabrata, Candida tropicalis, and Cryptococcus neoformans, with MICs at which 90% of isolates were inhibited of 0.03, 1, 0.5, and 0.5 microg/ml, respectively. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis
Only one new class of antifungal drugs has been introduced into clinical practice in the last 30 years, and thus the identification of small molecules with novel mechanisms of action is an important goal of current anti-infective research. Here, we describe the characterization of the spectrum of in vitro activity and in vivo activity ofAR-12, a celecoxib derivative which has been tested in a phase I clinical trial as an anticancer agent. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
NOAC-Drug Interactions Linked to Increased Bleeding NOAC-Drug Interactions Linked to Increased Bleeding
Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin was associated with increased risk for major bleeding compared with the use of NOACs alone in a new study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
FDA Drug Safety Communication:Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants
[8-03-2011] The U.S. Food and Drug Administration (FDA) is informing the public that chronic, high doses (400-800 mg/day) of the antifungal drug Diflucan (fluconazole) may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 4, 2017 Category: Drugs & Pharmacology Source Type: news
FTC approves Baxter ’ s $625m Claris buyout, with conditions
The Federal Trade Commission approved Baxter‘s (NYSE:BAX) $625 million acquisition of Claris Lifesciences‘ (BOM:533288) injectable drug biz, but mandated that the companies divest two drugs products – an antifungal agent, fluconazole, and intravenous milrinone.
The FTC filed a complaint saying that the original deal would likely reduce competition in the U.S. for fluconazole since Baxter and Claris represent two of the four significant competitors selling fluconazole in saline intravenous bags. Combined, they hold an estimated market share of 60%, according to the FTC.
Get the full story at our sister site, ...
Source: Mass Device - July 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Mergers & Acquisitions Pharmaceuticals Wall Street Beat Baxter Claris Lifesciences Source Type: news
The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.
Only one new class of antifungal drugs has been introduced into clinical practice in the last 30 years, and thus the identification of small molecules with novel mechanisms of action is an important goal of current anti-infective research. Here, we describe the characterization of the spectrum of in vitro activity and in vivo activity of AR-12, a celecoxib derivative which has been tested in a phase I clinical trial as an anticancer agent. AR-12 inhibits fungal acetyl coenzyme A (acetyl-CoA) synthetase in vitro and is fungicidal at concentrations similar to those achieved in human plasma. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans.
Vulvovaginal candidiasis/candidosis is a common fungal infection afflicting approximately 75% of women globally caused primarily by the yeast Candida albicans. Fluconazole is widely regarded as the antifungal drug of choice since its introduction in 1990 due to its high oral bioavailability, convenient dosing regimen and favourable safety profile. However, its widespread use has led to the emergence of fluconazole-resistant C. albicans, posing a universal clinical concern. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - April 24, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Drug-Resistant Fungus Spreads Among U.S. Healthcare Facilities
This article was updated from a Nov. 2016 story on C. auris.
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com.
-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - March 21, 2017 Category: Consumer Health News Source Type: news
Zydus gets USFDA nod for fungal infections, skin disorder drug
The company has received final approval from the USFDA to market Fluconazole tablets USP and Clobetasol Propionate Spray (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 17, 2017 Category: Pharmaceuticals Source Type: news
Zydus Cadila receives USFDA nod to market fluconazole tablets
The company also received approval for Clobetasol Propionate spray used in the treatment of various skin disorders. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 17, 2017 Category: Pharmaceuticals Source Type: news
The First Cases Of Drug-Resistant Fungus Candida Auris Found In The U.S.
A drug-resistant fungus that first emerged in the U.S. only a few years ago has been linked to four deaths, and health officials are on guard about its potential to spread in healthcare facilities throughout the country.
C. auris, a yeast that has sickened people around the globe and caused potentially deadly infections, appears to have arrived in the U.S. a few years ago, according to the first report on C. auris released by the U.S. Centers for Disease Control and Prevention.
Because C. auris cases have cropped up in other countries, the CDC decided to alert all U.S. clinics, labs...
Source: Healthy Living - The Huffington Post - November 5, 2016 Category: Consumer Health News Source Type: news
The First Cases Of Drug-Resistant Fungus Candida Auris Found In The U.S.
A drug-resistant fungus that first emerged in the U.S. only a few years ago has been linked to four deaths, and health officials are on guard about its potential to spread in healthcare facilities throughout the country.
C. auris, a yeast that has sickened people around the globe and caused potentially deadly infections, appears to have arrived in the U.S. a few years ago, according to the first report on C. auris released by the U.S. Centers for Disease Control and Prevention.
Because C. auris cases have cropped up in other countries, the CDC decided to alert all U.S. clinics, labs...
Source: Science - The Huffington Post - November 5, 2016 Category: Science Source Type: news
This Is The First Drug-Resistant Fungus Found In The U.S.
A drug-resistant fungus that first emerged in the U.S. only a few years ago has been linked to four deaths, and health officials are on guard about its potential to spread in healthcare facilities throughout the country.
C. auris, a yeast that has sickened people around the globe and caused potentially deadly infections, appears to have arrived in the U.S. a few years ago, according to the first report on C. auris released by the U.S. Centers for Disease Control and Prevention.
Because C. auris cases have cropped up in other countries, the CDC decided to alert all U.S. clinics, labs...
Source: Science - The Huffington Post - November 5, 2016 Category: Science Source Type: news
